Accretion Nutraveda (BOM:544694) EBIT: ₹66.9 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544694 Accretion Nutraveda Ltd BOM:544694
21 GF Score
Price ₹283.95
! 3 Warning Signs
View Full Analysis

What is Accretion Nutraveda EBIT?

Accretion Nutraveda BOM:544694 21 EBIT is ₹66.9 Mil as of Mar. 2026. GuruFocus rates BOM:544694 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review.

Accretion Nutraveda's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹35.7 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹66.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Accretion Nutraveda's annualized ROC % for the quarter that ended in Mar. 2026 was 21.25%. Accretion Nutraveda's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 36.28%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Accretion Nutraveda's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.21%.

Accretion Nutraveda  (BOM:544694) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Accretion Nutraveda's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=69.226 * ( 1 - 18.55% )/( (134.428 + 396.187)/ 2 )
=56.384577/265.3075
=21.25 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=163.494 - 29.031 - ( 0.035 - max(0, 71.055 - 144.855+0.035))
=134.428

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=417.938 - 8.993 - ( 12.758 - max(0, 25.39 - 362.273+12.758))
=396.187

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Accretion Nutraveda's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=71.46/( ( (18.638 + max(107.61, 0)) + (16.563 + max(251.092, 0)) )/ 2 )
=71.46/( ( 126.248 + 267.655 )/ 2 )
=71.46/196.9515
=36.28 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(79.692 + 51.276 + 12.699) - (29.031 + 0 + 7.026)
=107.61

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(81.117 + 89.949 + 100.949) - (8.993 + 0 + 11.93)
=251.092

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Accretion Nutraveda's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=66.881/2085.322
=3.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accretion Nutraveda EBIT Related Terms

Accretion Nutraveda EBIT Historical Data

* Premium members only.

The historical data trend for Accretion Nutraveda's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accretion Nutraveda EBIT Chart

Accretion Nutraveda Annual Data
Trend Mar23 Mar24 Mar25 Mar26
EBIT
4.48 11.36 35.08 67.46

Accretion Nutraveda Semi-Annual Data
Mar23 Mar24 Mar25 Sep25 Mar26
EBIT 0.00 0.00 24.68 31.15 35.73

BOM:544694 vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Accretion Nutraveda's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accretion Nutraveda EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accretion Nutraveda's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Accretion Nutraveda's EV-to-EBIT falls into.


BOM:544694
21GF Score
Accretion Nutraveda Ltd BOM:544694
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accretion Nutraveda EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹66.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹66.9 Mil mean?
Accretion Nutraveda (BOM:544694) has a EBIT of ₹66.9 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Accretion Nutraveda.
Is Accretion Nutraveda's EBIT too high?
Accretion Nutraveda's current EBIT is ₹66.9 Mil. Overall, Accretion Nutraveda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Nutraveda's EBIT compare to ZTS?
Accretion Nutraveda's EBIT of ₹66.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Accretion Nutraveda. Accretion Nutraveda's current EBIT is ₹66.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Nutraveda stock overvalued right now?
Accretion Nutraveda (BOM:544694) has a current EBIT of ₹66.9 Mil. The current EBIT is ₹66.9 Mil. Accretion Nutraveda's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Accretion Nutraveda (BOM:544694), the current EBIT is ₹66.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accretion Nutraveda Business Description

Address 27 Xcelon Industrial Park-1, Vasna-Chacharwadi, Taluka Sanand, Ahmedabad, GJ, IND, 382213
Accretion Nutraveda Ltd is engaged in the business of the Manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. It is a healthcare focused Company specializing in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA. The company offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. Its product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.
21GF Score

Get the complete analysis for BOM:544694

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹283.95
Price